Reference entry · Actin-sequestering repair protein
Thymosin Beta-4
Also known as: Tβ4 · Thymosin β4 · TB4 full length
- Class
- Actin-sequestering repair protein
- Size
- 43 amino acids
- Primary targets (literature)
- G-actin; cell migration and wound repair literature
- Regulatory context
- Development-stage wound formulations; not universally FDA-approved as generic catalog injectable. TB-500 fragments are separate research materials.
Overview
Thymosin beta-4 is the full-length actin-binding protein underlying TB-500 fragment commerce. Phase 2 wound and corneal trials exist; catalog fragments require separate sequence confirmation.
Mechanism in research literature
Sequesters monomeric actin to support cytoskeletal remodeling, cell migration, angiogenesis, and anti-fibrotic myofibroblast reduction in preclinical models.
Common research focus areas
- Dermal and corneal wound phase 2 trials
- Actin-binding domain LKKTETQ vs. full 43-mer
- Distinction from TB-500 catalog fragments
- MS length confirmation and endotoxin for sensitive assays
Full literature roundup
Read the cited research summary
The full 43-amino-acid actin-binding protein behind TB-500 fragment commerce. Wound-healing trials, actin sequestration biology, and sequence verification.
Thymosin Beta-4 research roundup · 4 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.